Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation

被引:31
|
作者
Finke, J. [1 ]
Schmoor, C. [2 ]
Bertz, H. [1 ]
Marks, R. [1 ]
Waesch, R. [1 ]
Zeiser, R. [1 ]
Hackanson, B. [1 ]
机构
[1] Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany
[2] Univ Med Ctr, Ctr Clin Trials & Biostat, Freiburg, Germany
关键词
ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; RISK; GRAFT; STRATEGIES; ANTIGENS; DONORS; IMPACT; INDEX; MDS;
D O I
10.1038/bmt.2015.338
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The outcome of patients with therapy-related myelodysplasia (t-MDS) or t-AML is very poor. The only curative treatment option implements allogeneic hematopoietic cell transplantation (aHCT); however, long-term follow-up data beyond 5 years are scarce. Here we report on a cohort of 79 consecutive patients with a median age of 58 years (range (r): 20-76) at transplantation and a median follow-up of 7.5 years (r: 0.07-19.0). Only 19 (24.1%) patients were in CR before aHCT. Non-relapse mortality and relapse rates were 23% (95% confidence interval, 15-35%) and 42% (32-55%) at 5 years, and 32% (22-46%) and 44% (34-57%) at 10 years, respectively. Disease-free survival (DFS) and overall survival (OS) rates were 35% (24-46%) and 38% (27-49%) at 5 years, and 24% (14-36%) and 24% (13-36%) at 10 years, respectively. Although cytogenetic aberrations were associated with shorter DFS and higher relapse risk, persistent disease at the time of transplantation, an unrelated donor and patient age were not associated with shorter OS. In conclusion, long-term survival beyond 10 years of t-MDS/t-AML patients after aHCT is possible, even for refractory patients. Therefore, early donor search and rapid transplantation are warranted, also to decrease the risk of disease-related deterioration of patients' performance status.
引用
收藏
页码:771 / 777
页数:7
相关论文
共 50 条
  • [1] Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer
    Omazic, Brigitta
    Remberger, Mats
    Barkholt, Lisbeth
    Soderdahl, Gunnar
    Potacova, Zuzana
    Wersall, Peter
    Ericzon, Bo-Goran
    Mattsson, Jonas
    Ringden, Olle
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (04) : 676 - 681
  • [2] Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up
    Shimoni, A.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Nagler, A.
    LEUKEMIA, 2010, 24 (05) : 1050 - 1052
  • [3] Long-term survival of patients with therapy-related myeloid neoplasms after allogeneic hematopoietic cell transplantation-more than just a myth
    Mukherjee, S.
    Gerds, A. T.
    BONE MARROW TRANSPLANTATION, 2016, 51 (06) : 763 - 764
  • [4] Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation
    Alam, N.
    Atenafu, E. G.
    Kuruvilla, J.
    Uhm, J.
    Lipton, J. H.
    Messner, H. A.
    Kim, D. H.
    Seftel, M.
    Gupta, V.
    BONE MARROW TRANSPLANTATION, 2015, 50 (09) : 1180 - 1186
  • [5] Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
    Maffini, Enrico
    Storer, Barry E.
    Sandmaier, Brenda M.
    Bruno, Benedetto
    Sahebi, Firoozeh
    Shizuru, Judith A.
    Chauncey, Thomas R.
    Hari, Parameswaran
    Lange, Thoralf
    Pulsipher, Michael A.
    McSweeney, Peter A.
    Holmberg, Leona
    Becker, Pamela S.
    Green, Damian J.
    Mielcarek, Marco
    Maloney, David G.
    Storb, Rainer
    HAEMATOLOGICA, 2019, 104 (02) : 380 - 391
  • [6] Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
    Jovein, Miriam Mozaffari
    Ihorst, Gabriele
    Duque-Afonso, Jesus
    Waesch, Ralph
    Bertz, Hartmut
    Wehr, Claudia
    Duyster, Justus
    Zeiser, Robert
    Finke, Juergen
    Scherer, Florian
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [7] Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
    Lin, Chenyu
    Schwarzbach, Aurelie
    Sanz, Jaime
    Montesinos, Pau
    Stiff, Patrick
    Parikha, Suhag
    Brunstein, Claudio
    Cutler, Corey
    Lindemans, Caroline A.
    Hanna, Rabi
    Koh, Liang Piu
    Jagasia, Madan H.
    Valcarcel, David
    Maziarz, Richard T.
    Keating, Amy K.
    Hwang, William Y. K.
    Rezvani, Andrew R.
    Karras, Nicole A.
    Fernandes, Juliana F.
    Rocha, Vanderson
    Badell, Isabel
    Ram, Ron
    Schiller, Gary J.
    Volodin, Leonid
    Walters, Mark C.
    Hamerschlak, Nelson
    Cilloni, Daniela
    Frankfurt, Olga
    McGuirk, Joseph P.
    Kurtzberg, Joanne
    Sanz, Guillermo
    Simantov, Ronit
    Horwitz, Mitchell E.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (05): : 338e1 - 338e6
  • [8] Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy
    Jaimes-Albornoz, Daniel
    Mannone, Lionel
    Nguyen-Quoc, Stephanie
    Chalandon, Yves
    Chevallier, Patrice
    Mohty, Mohamad
    Meunier, Mathieu
    Robin, Marie
    Ledoux, Marie-Pierre
    Guillerm, Gaelle
    Bay, Jacques-Olivier
    Poire, Xavier
    Maillard, Natacha
    Leclerc, Mathieu
    Daguindau, Etienne
    Beguin, Yves
    Rubio, Marie Therese
    Gyan, Emmanuel
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (12) : 2366 - 2374
  • [9] Subsequent malignancies after long-term follow-up of pediatric hematopoietic stem cell transplantation
    Sisinni, Luisa
    Gich, Ignasi
    Torrent, Monserrat
    Badell, Isabel
    ANALES DE PEDIATRIA, 2019, 90 (03): : 157 - 164
  • [10] Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
    Aldoss, Ibrahim
    Pham, Anh
    Li, Sierra Min
    Gendzekhadze, Ketevan
    Afkhami, Michelle
    Telatar, Milhan
    Hong, Hao
    Padeganeh, Abbas
    Bedell, Victoria
    Cao, Thai
    Khaled, Samer K.
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Ali, Haris
    Aribi, Ahmed
    Palmer, Joycelynne
    Aoun, Patricia
    Spielberger, Ricardo
    Stein, Anthony S.
    Snyder, David
    O'Donnell, Margaret R.
    Murata-Collins, Joyce
    Senitzer, David
    Weisenburger, Dennis
    Forman, Stephen J.
    Pullarkat, Vinod
    Marcucci, Guido
    Pillai, Raju
    Nakamura, Ryotaro
    HAEMATOLOGICA, 2017, 102 (12) : 2030 - 2038